Navigation Links
Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
Date:4/29/2008

Demonstration Signifies Completion of First Disease Database for the

VentriPoint Diagnostic System

SEATTLE, April 29 /PRNewswire/ -- VentriPoint Diagnostics today announced that Knowledge Based Reconstruction (KBR) enables accurate three dimensional reconstruction of right ventricular volume and function in patients with tetralogy of fallot (TOF) in significantly less time and for a lower cost than currently applied methods.

TOF is a disease that impacts the heart in multiple ways, such as creating a hole between the ventricles and developing levels of obstruction from the right ventricle to the lungs known as pulmonary stenosis. The three dimensional models also provided an understanding of changes to the shape of the right ventricle that doctors can use to analyze how the heart adapts to hemodynamic overload.

In a study of 20 patients with repaired TOF led by Florence H. Sheehan, M.D., of the University of Washington, the accuracy of the volume and ejection fraction of the right ventricle obtained with KBR was equal to or greater than the published accuracy of other methods of measurement. Using the VentriPoint Diagnostic System, KBR was applied as anatomical points identified on two dimensional images of the right ventricle of TOF diseased hearts were referenced with the KBR database comprised of 110 patients, including 54 with TOF. This is the first of four unique disease-specific KBR databases that VentriPoint is developing and plans to deploy when the VentriPoint Diagnostic System becomes commercially available.

"Applying Knowledge Based Reconstruction, our VentriPoint Diagnostic System completes critical ventricular measurements in significantly less time and lower cost than traditional methods to enable the cardiologists to better diagnose, monitor and track the efficacy of treatments," said Joseph Ashley, CEO of VentriPoint Diagnostics. "This validation of the tetralogy of fallot Knowledge Based Re
'/>"/>

SOURCE VentriPoint Diagnostics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
4. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Diplomat Specialty Pharmacy Honored By Inc Magazine As One Of The Nations Fastest Growing Companies 54351 1Diplomat Specialty Pharmacy Honored By Inc Magazine As One Of The Nations Fastest Growing Companies 54351 2New Contract Awards May Shift Thousands of Medicaid Enrollees in Michigan 54347 1New Contract Awards May Shift Thousands of Medicaid Enrollees in Michigan 54347 2New Antibiotics May Target Cancer Causing Proteins 54343 1